Lecozotan

Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients. , the first Phase III clinical trial has been completed.

Method of action
Lecozotan is a competitive, selective 5-HT1A receptor antagonist which enhances the potassium-stimulated release of acetylcholine and glutamate.